Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 10/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.44 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.42 |
| ▸ | BCR | P11274 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929524 | 0.92 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2ACYP2C19HTT | |
| SCHEMBL2926843 | 0.92 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1KMT2ACYP2C19HTT | |
| SCHEMBL2921169 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2MEN1KMT2ACYP2C19HTT | |
| SCHEMBL2927272 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ACYP2C19HTT | |
| SCHEMBL2923195 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2MEN1KMT2ACYP2C19HTT | |
| SCHEMBL2928406 | 0.90 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2ACYP2C19HTT | |
| SCHEMBL20393353 | 0.88 | MEN1 (0.51) | SMN1; SMN2MEN1KMT2AMAPTAURKA | |
| SCHEMBL4282647 | 0.86 | TAAR1 (0.43) | AURKAAURKBABL1BCRNTRK1 | |
| SCHEMBL4281362 | 0.86 | ALK (0.39) | SMN1; SMN2MEN1KMT2ACYP2C19HTT | |
| SCHEMBL4278011 | 0.85 | MAPT (0.47) | SMN1; SMN2MEN1KMT2AHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644376-B1 | PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-09-08 | — | — | EP | disclosed |
| US-7582628-B2 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-09-01 | — | — | US | disclosed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
| US-20060276471-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (FORMERLY PHARMACIA ITALIA S.P.A.) (IT) | 2006-12-07 | — | — | US | disclosed |
| US-7141568-B2 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-28 | — | — | US | disclosed |
| EP-1644376-A1 | PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2006-04-12 | — | — | EP | disclosed |
| US-20050032839-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
| WO-2005005427-A1 | PYRROLO[3,4-c]PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | SMN1; SMN2 2238/4885MEN1 3150/4885KMT2A 2155/4885 |
| US-20050032839-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K3, MAP3K19, MAP3K9 | SMN1; SMN2 4283/4885MEN1 3542/4885KMT2A 1990/4885 |
| US-20060276471-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K3, MAP3K19, MAP3K9 | SMN1; SMN2 4283/4885MEN1 3542/4885KMT2A 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.